RT Book, Section
A1 Cohen, Philip R.
A1 Kurzrock, Razelle
A2 Kang, Sewon
A2 Amagai, Masayuki
A2 Bruckner, Anna L.
A2 Enk, Alexander H.
A2 Margolis, David J.
A2 McMichael, Amy J.
A2 Orringer, Jeffrey S.
SR Print(0)
ID 1161329109
T1 Sweet Syndrome
T2 Fitzpatrick's Dermatology, 9e
YR 2019
FD 2019
PB McGraw-Hill Education
PP New York, NY
SN 9780071837798
LK dermatology.mhmedical.com/content.aspx?aid=1161329109
RD 2024/04/19
AB AT-A-GLANCESweet  syndrome,  also  referred  to  as  acute  febrile  neutrophilic  dermatosis,  is  characterized  by  a  constellation  of  symptoms  and  findings:  the  acute  onset  of  fever,  neutrophilia,  tender  erythematous  skin  lesions  that  typically  show  mature  neutrophils  in  the  upper  dermis,  and—after  initiation  of  systemic  corticosteroids—a  prompt  improvement  of  both  symptoms  and  lesions.Extracutaneous  manifestations  of  Sweet  syndrome  can  include  cardiovascular,  central  nervous  system,  gastrointestinal,  hepatic,  musculoskeletal,  ocular,  oral,  otic,  pulmonary,  renal,  and  splenic  organs.Infection  of  the  upper  respiratory  tract  and/or  gastrointestinal  tract,  inflammatory  bowel  disease,  and  pregnancy  may  be  associated  with  classical  Sweet  syndrome.In  individuals  with  previously  undiagnosed  or  relapsing  hematologic  malignancies  and  solid  tumors,  malignancy-associated  Sweet  syndrome  may  occur  as  a  cutaneous  paraneoplastic  syndrome.The  onset  of  the  dermatosis  in  patients  following  the  initiation  of  certain  medications—drug-induced  Sweet  syndrome—is  most  commonly  associated  with  granulocyte  colony-stimulating  factor.The  pathogenesis  of  Sweet  syndrome  remains  to  be  established;  cytokines—directly  or  indirectly—may  have  an  important  etiologic  role.Corticosteroids,  potassium  iodide,  and  colchicine  are  the  first-line  oral  systemic  agents  for  treating  Sweet  syndrome.Indomethacin,  clofazimine,  cyclosporine,  and  dapsone  are  the  second-line  oral  systemic  agents  for  treating  Sweet  syndrome.Localized  Sweet  syndrome  lesions  may  be  effectively  treated  with  the  topical  application  of  high-potency  corticosteroids  or  intralesional  corticosteroids.